Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Bruton tyrosine kinase (BTK) plays a functional and integral role in B-cell receptor (BCR) signalling and is expressed in normal and malignant B cells. Given BTK’s central role in the survival and proliferation of malignant B cells, BTK inhibitors have been developed for use in various B-cell malignancies, with several US Food and Drug Administration approvals in […]

Robin Foà, ASH 2021: Measurable Residual Disease in the Management of Haematological Malignancies (PART ONE)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 9th 2021

We were delighted to catch up with touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) to discuss his educational session at the 63rd ASH Annual Meeting & Exposition on measurable residual disease in the management of many haematological malignancies. (PART ONE)

Question
What are the take-home messages from your educational session on measurable residual disease (MRD) at the ASH Annual Meeting & Exposition this year?

Speaker Disclosure: Robin Foà has no financial or non-financial conflicts of interest to declare in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.

Filmed in coverage of the 63rd ASH Annual Meeting & Exposition

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup